Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681601 | 0.90 | MAP2K1 (0.45) | MAP2K1MAP2K2CA2CHEK1MAPK10 | |
| SCHEMBL1681842 | 0.89 | MAP2K1 (0.42) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1681405 | 0.86 | MAP2K1 (0.42) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL1681767 | 0.86 | HTR2C (0.36) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1681751 | 0.83 | MAP2K1 (0.49) | MAP2K1MAP2K2CA2 | |
| SCHEMBL1681101 | 0.81 | MAP2K1 (0.41) | MAP2K1MAP2K2CA2CHEK1MAPK10 | |
| SCHEMBL390628 | 0.81 | PIM1 (0.47) | MAP2K1MAP2K2CA2CHEK1MAPK10 | |
| SCHEMBL20385575 | 0.81 | MAP2K1 (0.45) | MAP2K1MAP2K2CA2CHEK1MAPK10 | |
| SCHEMBL345623 | 0.80 | MAP2K1 (0.52) | MAP2K1MAP2K2CA2CHEK1MAPK10 | |
| SCHEMBL20385579 | 0.80 | MAP2K1 (0.44) | MAP2K1MAP2K2CA2CHEK1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-B1 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2488507-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | Allostem Therapeutics LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | MYLK2, MAPK1, MAP3K1 | MAP2K1 100/4885MAP2K2 80/4885CA2 3923/4885 |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | NRAS, BRAF, MAP3K20 | MAP2K1 205/4885MAP2K2 147/4885CA2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.